Activation mechanism of endothelin ET B receptor by endothelin-1

Nature

Volumn 537, Issue 7620, 2016, Pages 363-368

  Shihoya, Wataru ^a,b   Nishizawa, Tomohiro ^b,c   Okuta, Akiko ^a   Tani, Kazutoshi ^a   Dohmae, Naoshi ^d   Fujiyoshi, Yoshinori ^a   Nureki, Osamu ^b   Doi, Tomoko ^e  

^a NAGOYA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d RIKEN Center for Sustainable Resource Science   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN 3; ENDOTHELIN B RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; MUSCARINIC M2 RECEPTOR; PEPTIDE;

CRYSTAL STRUCTURE; GENE EXPRESSION; LIGAND; MUTATION; PEPTIDE; PHYSIOLOGICAL RESPONSE; PROTEIN;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; AGONISTS; ALLOSTERISM; BINDING SITE; CELL MEMBRANE; CHEMISTRY; ENZYME SPECIFICITY; GENETICS; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; CELL MEMBRANE; CRYSTALLOGRAPHY, X-RAY; ENDOTHELIN-1; ENDOTHELIN-3; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTOR, ENDOTHELIN B; RECEPTOR, MUSCARINIC M2; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 84988355024     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature19319     Document Type: Article

References (65)

1. Yanagisawa, M., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415 (1988
2. Barton, M., & Yanagisawa, M. Endothelin: 20 years from discovery to therapy. Can. J. Physiol. Pharmacol. 86, 485-498 (2008
3. Kedzierski, R. M., & Yanagisawa, M. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 41, 851-876 (2001
4. Kohan, D. E., Rossi, N. F., Inscho, E. W., & Pollock, D. M. Regulation of blood pressure and salt homeostasis by endothelin. Physiol. Rev. 91, 1-77 (2011
5. Rubanyi, G. M., & Polokoff, M. A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46, 325-415 (1994
6. Davenport, A. P. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev. 54, 219-226 (2002
7. Desmarets, J., Gresser, O., Guedin, D., & Frelin, C. Interaction of endothelin-1 with cloned bovine ETA receptors: biochemical parameters and functional consequences. Biochemistry 35, 14868-14875 (1996
8. Mey, J. G. R. D., Compeer, M. G., & Meens, M. J. Endothelin-1, an endogenous irreversible agonist in search of an allosteric inhibitor. Mol. Cell. Pharmacol. 1, 246-257 (2009
9. Takasuka, T., Sakurai, T., Goto, K., Furuichi, Y., & Watanabe, T. Human endothelin receptor ETB. Amino acid sequence requirements for super stable complex formation with its ligand. J. Biol. Chem. 269, 7509-7513 (1994
10. Hilal-Dandan, R., Villegas, S., Gonzalez, A., & Brunton, L. L. The quasiirreversible nature of endothelin binding and G protein-linked signaling in cardiac myocytes. J. Pharmacol. Exp. Ther. 281, 267-273 (1997
11. Doi, T., Sugimoto, H., Arimoto, I., Hiroaki, Y., & Fujiyoshi, Y. Interactions of endothelin receptor subtypes A and B with Gi, Go, and Gq in reconstituted phospholipid vesicles. Biochemistry 38, 3090-3099 (1999
12. Maguire, J. J., et al. Comparison of human ETA and ETB receptor signalling via G-protein and β-Arrestin pathways. Life Sci. 91, 544-549 (2012
13. Rosan?, L., et al. β-Arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc. Natl Acad. Sci. USA 106, 2806-2811 (2009
14. Bremnes, T., et al. Regulation and intracellular trafficking pathways of the endothelin receptors. J. Biol. Chem. 275, 17596-17604 (2000
15. Rosanò, L., Spinella, F., & Bagnato, A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nature Rev. Cancer 13, 637-651 (2013
16. Remuzzi, G., Perico, N., & Benigni, A. New therapeutics that antagonize endothelin: promises and frustrations. Nature Rev. Drug Discov. 1, 986-1001 (2002
17. Clozel, M., et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 365, 759-761 (1993
18. Sidharta, P. N., van Giersbergen, P. L., Halabi, A., & Dingemanse, J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur. J. Clin. Pharmacol. 67, 977-984 (2011
19. Vatter, H., & Seifert, V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc. Drug Rev. 24, 63-76 (2006
20. Maguire, J. J., & Davenport, A. P. Endothelin@25-new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br. J. Pharmacol. 171, 5555-5572 (2014
21. Ballesteros, J. A. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366-428 (1995
22. Okuta, A., Tani, K., Nishimura, S., Fujiyoshi, Y., & Doi, T. Thermostabilization of the human endothelin type-B receptor. J. Mol. Biol. 428, 2265-2274 (2016
23. Venkatakrishnan, A. J., et al. Molecular signatures of G-protein-coupled receptors. Nature 494, 185-194 (2013
24. White, J. F., et al. Structure of the agonist-bound neurotensin receptor. Nature 490, 508-513 (2012
25. Qin, L., et al. Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science 347, 1117-1122 (2015
26. Chen, J., Sawyer, N., & Regan, L. Protein-protein interactions: general trends in the relationship between binding affinity and interfacial buried surface area. Protein Sci. 22, 510-515 (2013
27. Janes, R. W., Peapus, D. H., & Wallace, B. A. The crystal structure of human endothelin. Nature Struct. Biol. 1, 311-319 (1994
28. Takashima, H., et al. Distributed computing and NMR constraint-based high-resolution structure determination: applied for bioactive Peptide endothelin-1 to determine C-Terminal folding. J. Am. Chem. Soc. 126, 4504-4505 (2004
29. Andersen, N. H., Chen, C. P., Marschner, T. M., Krystek, S. R. Jr. & Bassolino, D. A. Conformational isomerism of endothelin in acidic aqueous media: a quantitative NOESY analysis. Biochemistry 31, 1280-1295 (1992
30. Lättig, J., Oksche, A., Beyermann, M., Rosenthal, W., & Krause, G. Structural determinants for selective recognition of peptide ligands for endothelin receptor subtypes ETA and ETB. J. Pept. Sci. 15, 479-491 (2009
31. Tam, J. P., et al. Alanine scan of endothelin: importance of aromatic residues. Peptides 15, 703-708 (1994
32. Galantino, M., et al. D-Amino acid scan of endothelin: importance of amino acids adjacent to cysteinyl residues in isomeric selectivity. Pept. Res. 8, 154-159 (1995
33. Saeki, T., Ihara, M., Fukuroda, T., Yamagiwa, M., & Yano, M. [Ala1, 3, 11, 15] endothelin-1 analogs with ETB agonistic activity. Biochem. Biophys. Res. Commun. 179, 286-292 (1991
34. Nakajima, K., et al. Structure-Activity relationship of endothelin: importance of charged groups. Biochem. Biophys. Res. Commun. 163, 424-429 (1989
35. Ergul, A., Tackett, R. L., & Puett, D. Identification of receptor binding and activation sites in endothelin-1 by use of site-directed mutagenesis. Circ. Res. 77, 1087-1094 (1995
36. Lee, J. A., et al. Lysine 182 of endothelin B receptor modulates agonist selectivity and antagonist affinity: evidence for the overlap of peptide and non-peptide ligand binding sites. Biochemistry 33, 14543-14549 (1994
37. Talbodec, A., et al. Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol. Pharmacol. 57, 797-804 (2000
38. Kikuchi, T., et al. Endothelin-1 analogues substituted at both position 18 and 19: highly potent endothelin antagonists with no selectivity for either receptor subtype ETA or ETB. J. Med. Chem. 36, 4087-4093 (1993
39. Kruse, A. C., et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101-106 (2013
40. Krumm, B. E., White, J. F., Shah, P., & Grisshammer, R. Structural prerequisites for G-protein activation by the neurotensin receptor. Nature Commun. 6, 7895 (2015
41. Huang, W., et al. Structural insights into μ-opioid receptor activation. Nature 524, 315-321 (2015
42. Rasmussen, S. G., et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011
43. Nygaard, R., et al. The dynamic process of β2-Adrenergic receptor activation. Cell 152, 532-542 (2013
44. Sounier, R., et al. Propagation of conformational changes during μ-opioid receptor activation. Nature 524, 375-378 (2015
45. Katritch, V., et al. Allosteric sodium in class A GPCR signaling. Trends Biochem. Sci. 39, 233-244 (2014
46. Standfuss, J., et al. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471, 656-660 (2011
47. Xu, F., et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322-327 (2011
48. Takasuka, T., Adachi, M., Miyamoto, C., Furuichi, Y., & Watanabe, T. Characterization of endothelin receptors ETA and ETB expressed in COS cells. J. Biochem. 112, 396-400 (1992
49. Serrano-Vega, M. J., Magnani, F., Shibata, Y., & Tate, C. G. Conformational thermostabilization of the β1-Adrenergic receptor in a detergent-resistant form. Proc. Natl Acad. Sci. USA 105, 877-882 (2008
50. Hattori, M., Hibbs, R. E., & Gouaux, E. A fluorescence-detection size-exclusion chromatography-based thermostability assay for membrane protein precrystallization screening. Structure 20, 1293-1299 (2012
51. Okamoto, Y., et al. Palmitoylation of human endothelinB. Its critical role in G protein coupling and a differential requirement for the cytoplasmic tail by G protein subtypes. J. Biol. Chem. 272, 21589-21596 (1997
52. Cherezov, V., et al. High-resolution crystal structure of an engineered human β2-Adrenergic G protein-coupled receptor. Science 318, 1258-1265 (2007
53. Thorsen, T. S., Matt, R., Weis, W. I., & Kobilka, B. K. Modified T4 lysozyme fusion proteins facilitate G protein-coupled receptor crystallogenesis. Structure 22, 1657-1664 (2014
54. Caffrey, M., & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706-731 (2009
55. Kabsch, W. Xds. Acta Crystallogr. D 66, 125-132 (2010
56. McCoy, A. J., et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007
57. Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010
58. Adams, P. D., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213-221 (2010
59. Chen, V. B., et al. MolProbity: all-Atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010
60. Doi, T., et al. Characterization of human endothelin B receptor and mutant receptors expressed in insect cells. Eur. J. Biochem. 248, 139-148 (1997
61. Wada, K., et al. Purification of an endothelin receptor from human placenta. Biochem. Biophys. Res. Commun. 167, 251-257 (1990
62. Elshourbagy, N. A., et al. Molecular cloning and characterization of the major endothelin receptor subtype in porcine cerebellum. Mol. Pharmacol. 41, 465-473 (1992
63. Aumelas, A., et al. [Lys(-2)-Arg(-1)]endothelin-1 solution structure by two-dimensional 1H-NMR: possible involvement of electrostatic interactions in native disulfide bridge formation and in biological activity decrease. Biochemistry 34, 4546-4561 (1995
64. Wallace, A. C., Laskowski, R. A., & Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127-134 (1995
65. Robert, X., & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, W320-W324 (2014